MX2017016801A - Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso. - Google Patents

Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.

Info

Publication number
MX2017016801A
MX2017016801A MX2017016801A MX2017016801A MX2017016801A MX 2017016801 A MX2017016801 A MX 2017016801A MX 2017016801 A MX2017016801 A MX 2017016801A MX 2017016801 A MX2017016801 A MX 2017016801A MX 2017016801 A MX2017016801 A MX 2017016801A
Authority
MX
Mexico
Prior art keywords
drospirenone
female patient
patient affected
excess weight
contraceptive
Prior art date
Application number
MX2017016801A
Other languages
English (en)
Other versions
MX389310B (es
Inventor
Drouin Dominique
Boyer-Joubert Cécile
Perrin Philippe
Original Assignee
Laboratorios Leon Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56178376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017016801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP15305965.4A external-priority patent/EP3108889A1/en
Priority claimed from CN201510348953.1A external-priority patent/CN106265694A/zh
Application filed by Laboratorios Leon Farma Sa filed Critical Laboratorios Leon Farma Sa
Publication of MX2017016801A publication Critical patent/MX2017016801A/es
Publication of MX389310B publication Critical patent/MX389310B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La drospirenona como el único ingrediente anticonceptivo comprendido en una unidad de dosificación diaria activa en una cantidad de al menos 3 mg para su uso como anticonceptivo para una paciente mujer con afección de obesidad.
MX2017016801A 2015-06-23 2016-06-23 Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso. MX389310B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305965.4A EP3108889A1 (en) 2015-06-23 2015-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight
CN201510348953.1A CN106265694A (zh) 2015-06-23 2015-06-23 用于过重女性患者的基于屈螺酮的避孕药
PCT/EP2016/064574 WO2016207298A1 (en) 2015-06-23 2016-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight

Publications (2)

Publication Number Publication Date
MX2017016801A true MX2017016801A (es) 2018-05-11
MX389310B MX389310B (es) 2025-03-20

Family

ID=56178376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016801A MX389310B (es) 2015-06-23 2016-06-23 Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.

Country Status (26)

Country Link
EP (1) EP3313408B1 (es)
JP (1) JP6827962B2 (es)
KR (1) KR102217942B1 (es)
CN (2) CN113750108B (es)
AU (1) AU2016282863B2 (es)
BR (1) BR112017028048A2 (es)
CA (1) CA2989975C (es)
DK (1) DK3313408T3 (es)
EA (1) EA036497B1 (es)
ES (1) ES2970532T3 (es)
FI (1) FI3313408T3 (es)
HR (1) HRP20240121T8 (es)
HU (1) HUE065350T2 (es)
LT (1) LT3313408T (es)
MX (1) MX389310B (es)
MY (1) MY187233A (es)
NI (1) NI201700173A (es)
PH (1) PH12017502379A1 (es)
PL (1) PL3313408T3 (es)
RS (1) RS65196B1 (es)
SI (1) SI3313408T1 (es)
SM (1) SMT202400062T1 (es)
SV (1) SV2017005602A (es)
UA (1) UA122873C2 (es)
WO (1) WO2016207298A1 (es)
ZA (1) ZA201800067B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
DK3313408T3 (da) 2015-06-23 2024-01-29 Laboratorios Leon Farma Sa Drospirenon-baseret svangerskabsforebyggende middel til en kvindelig patient, som lider af overvægt
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
CN107875388A (zh) * 2004-04-30 2018-04-06 拜耳知识产权有限责任公司 对延长的激素避孕方案中突破性出血的控制
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20060009428A1 (en) * 2004-07-07 2006-01-12 Wyeth Cyclic progestin regimens and kits
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
PT1746101E (pt) 2005-07-21 2008-10-27 Bayer Schering Pharma Ag Processo para o fabrico de 3-oxo-pregn-4-eno-21,17-carbolactonas por meio de oxidação isenta de metais de 17-(3-hidroxipropil)-3,17-di-hidroxiandrostanos
BRPI0810049A2 (pt) * 2007-04-05 2015-05-05 Bayer Schering Pharma Ag Regime de drospirenona/17beta-estradiol, produto de combinação farmacêutica e kit para realizar esse regime
EP2548881B1 (en) * 2010-03-16 2014-12-17 Taizhou Taifa Pharmaceuticals Co., Ltd Preparation method of drospirenone
RU2422824C1 (ru) * 2010-05-07 2011-06-27 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ выбора тактики лечения нарушений менструального цикла у девочек-подростков с избыточной массой тела
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CN103372015A (zh) * 2012-04-19 2013-10-30 国家人口计生委科学技术研究所 包含屈螺酮或屈螺酮和雌激素的阴道环制剂
RU2527357C1 (ru) * 2013-08-02 2014-08-27 Государственное бюджетное образовательное Учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации (МГМСУ имени А.И. Евдокимова" Минздрава России) Способ персонифицированной профилактики эстрогензависимых заболеваний у здоровых женщин и женщин с факторами сердечно-сосудистого риска в возрасте 45-60 лет
DK3313408T3 (da) 2015-06-23 2024-01-29 Laboratorios Leon Farma Sa Drospirenon-baseret svangerskabsforebyggende middel til en kvindelig patient, som lider af overvægt

Also Published As

Publication number Publication date
EA036497B1 (ru) 2020-11-17
HUE065350T2 (hu) 2024-05-28
UA122873C2 (uk) 2021-01-13
PL3313408T3 (pl) 2024-04-15
JP2018527305A (ja) 2018-09-20
LT3313408T (lt) 2024-03-12
CA2989975C (en) 2021-10-12
KR20180019173A (ko) 2018-02-23
HK1255216A1 (zh) 2019-08-09
AU2016282863A1 (en) 2018-02-08
SV2017005602A (es) 2018-08-14
SI3313408T1 (sl) 2024-04-30
CA2989975A1 (en) 2016-12-29
HRP20240121T8 (hr) 2024-05-10
NI201700173A (es) 2018-04-02
BR112017028048A2 (pt) 2018-09-04
AU2016282863B2 (en) 2021-05-27
CN113750108B (zh) 2025-08-19
SMT202400062T1 (it) 2024-03-13
CN108025014A (zh) 2018-05-11
ZA201800067B (en) 2019-07-31
HRP20240121T1 (hr) 2024-04-12
MX389310B (es) 2025-03-20
JP6827962B2 (ja) 2021-02-10
FI3313408T3 (fi) 2024-01-25
DK3313408T3 (da) 2024-01-29
ES2970532T3 (es) 2024-05-29
CN108025014B (zh) 2021-10-22
WO2016207298A1 (en) 2016-12-29
NZ739195A (en) 2024-04-26
CN113750108A (zh) 2021-12-07
KR102217942B1 (ko) 2021-02-19
EA201792595A1 (ru) 2018-06-29
MY187233A (en) 2021-09-13
EP3313408B1 (en) 2023-12-06
PH12017502379A1 (en) 2018-06-25
RS65196B1 (sr) 2024-03-29
EP3313408A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
MX389310B (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
BR112017028140A2 (pt) formulações farmacêuticas
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
NZ719936A (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
CL2020000812A1 (es) Semaglutida en la terapia médica.
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
CL2016000397A1 (es) Tratamiento contra el cáncer
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
ECSP19024033A (es) Composiciones de tesofensina
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido